Recent Updates
Recently added Catalysts
PTCT Positive Sentiment

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 2, 2026, the company approved 300 restricted stock units ( RSUs ), each...

Thursday, January 8, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: PTC Therapeutics, Inc. has announced the approval of 300 restricted stock units (RSUs) to a newly hired non-executive employee as an inducement for accepting the position. This decision was endorsed by the company's Compensation Committee and complies with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over a four-year period, with portions of the shares vesting annually. This initiative reflects PTC's commitment to attract talent while adhering to industry regulations.
Price reaction · baseline $77.24 (2026-01-07 close) · hit after-hours · 2 other PTCT headline(s) in the window, move may be shared
day 0 close
-0.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • PTC Therapeutics approved 300 restricted stock units (RSUs) for a new non-executive employee.
  • The inducement grant aligns with Nasdaq Listing Rule, demonstrating regulatory compliance.
  • The vesting schedule incentivizes long-term commitment from the employee.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+74%
120-day peak, hindsight
Typical move
6.6%
average across 4 past catalysts
Lead asset
Ataluren
Phase 3 · Cystic Fibrosis

Full Press Release Details

WARREN, N.J. , Jan. 8, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on Jan. 2, 2026, the company approved 300 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to a new non-executive employee. The award was made pursuant to the Nasdaq inducement grant exception as a component of the new hire's employment compensation.
The inducement grant was approved by PTC's Compensation Committee on Jan. 2, 2026, and is being made as an inducement material to the employee's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs each will vest over four years, with 25% of the original number of shares vesting on each annual anniversary of the employee's new hire date until fully vested, subject to the employee's continued service with the company through the vesting dates.
For more information, please contact:

Frequently Asked Questions

What are the RSUs approved by PTC Therapeutics?

PTC Therapeutics approved 300 restricted stock units (RSUs) for a new employee.

What is the vesting period for the RSUs?

The RSUs will vest over four years, 25% annually on each anniversary.

Why were the RSUs granted to the employee?

The RSUs were granted as part of an inducement for the employee's acceptance.

Who approved the RSU grant at PTC Therapeutics?

The Compensation Committee approved the RSU grant on January 2, 2026.

What is the condition for RSU vesting?

Vesting is contingent on the employee's continued service with PTC.

ShareAdd on Google
Tags: PTCT Viatris Investor Conferences Healthcare PTC Therapeutics restricted stock units RSUs employment inducement NASDAQ: PTCT
Last updated: Jan 8, 2026

Biotech snapshot

Cash runway
$2229M liquidity · $0M/mo burn
Low dilution risk
Lead asset
AtalurenPhase 3
Cystic Fibrosis →

Catalyst track record

+74%
best trade around PTCT's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for PTCT.

See every catalyst's timing & PoA →